Cronos Group Inc banner

Cronos Group Inc
TSX:CRON

Watchlist Manager
Cronos Group Inc Logo
Cronos Group Inc
TSX:CRON
Watchlist
Price: 3.78 CAD 2.16% Market Closed
Market Cap: CA$1.4B

EV/EBITDA

-572.8
Current
68 662%
Cheaper
vs 3-y average of 0.8

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
-572.8
=
Enterprise Value
CA$221.1m
/
EBITDA
$-391k

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
-572.8
=
Enterprise Value
CA$221.1m
/
EBITDA
$-391k

Valuation Scenarios

Cronos Group Inc is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (0.8), the stock would be worth CA$-0.01 (100% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-102%
Maximum Upside
No Upside Scenarios
Average Downside
101%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple -572.8 CA$3.78
0%
3-Year Average 0.8 CA$-0.01
-100%
Industry Average 7.9 CA$-0.05
-101%
Country Average 10.2 CA$-0.07
-102%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
CA$221.1m
/
Jan 2026
$-391k
=
-572.8
Current
CA$221.1m
/
Dec 2026
$12.6m
=
17.6
Forward
CA$221.1m
/
Dec 2027
$42.1m
=
5.2
Forward
CA$221.1m
/
Dec 2028
$55.7m
=
4
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CA
Cronos Group Inc
TSX:CRON
1.4B CAD -572.8 -112
US
Eli Lilly and Co
NYSE:LLY
853.2B USD 28 41.3
US
Johnson & Johnson
NYSE:JNJ
544.6B USD 16.6 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.6 19.6
UK
AstraZeneca PLC
LSE:AZN
225.8B GBP 16.2 29.3
CH
Novartis AG
SIX:NOVN
226.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
278.5B USD 9.5 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8 10.8
US
Pfizer Inc
NYSE:PFE
155.3B USD 7.7 20
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 7.2 17
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Cronos Group Inc
TSX:CRON
Average EV/EBITDA: 50.4
Negative Multiple: -572.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28
21%
1.3
US
Johnson & Johnson
NYSE:JNJ
16.6
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.2
12%
1.4
CH
Novartis AG
SIX:NOVN
12.4
5%
2.5
US
Merck & Co Inc
NYSE:MRK
9.5
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.7
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
P/E Multiple
Earnings Growth PEG
CA
Cronos Group Inc
TSX:CRON
Average P/E: 22.1
Negative Multiple: -112
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.3
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.9
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.3
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
20
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1

Market Distribution

Lower than 100% of companies in Canada
Percentile
0th
Based on 2 002 companies
0th percentile
-572.8
Low
0 — 7
Typical Range
7 — 14.5
High
14.5 —
Distribution Statistics
Canada
Min 0
30th Percentile 7
Median 10.2
70th Percentile 14.5
Max 13 731.1

Cronos Group Inc
Glance View

Market Cap
1.4B CAD
Industry
Pharmaceuticals

Cronos Group, Inc. engages in the production and distribution of cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-05-07. The firm is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd, Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd. and Cronos Israel G.S. Pharmacy Ltd.

CRON Intrinsic Value
1.91 CAD
Overvaluation 49%
Intrinsic Value
Price CA$3.78
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett